For the rare inherited metabolic disease methylmalonic acidemia, current treatment options remain severely limited — dietary restriction, cofactor supplementation, and organ transplantation — leaving most patients facing progressive organ damage, neurological decline, and shortened lifespans. A preclinical study now demonstrates that a single liver-targeted lentiviral gene therapy can normalize the underlying biochemical defect and sustain that correction for over a year, a finding that could meaningfully shift the therapeutic horizon for this condition.

The research team administered a lentiviral vector encoding a functional copy of the MMUT gene — which normally instructs mitochondria to process methylmalonyl-CoA — to two-week-old MMA mice, an age roughly analogous to early infancy. A single systemic injection produced rapid and sustained therapeutic effects lasting beyond twelve months, including normalization of liver histology and mitochondrial ultrastructure. Critically, the intervention reduced methylmalonic acid accumulation in both the kidney and brain, organs that suffer the most severe long-term damage in affected patients. The researchers further developed a codon-optimized MMUT transgene variant that achieved over 80% hepatocyte transduction efficiency at lower vector doses, with corrected cells demonstrating a selective proliferative advantage — a potentially self-reinforcing benefit in a growing pediatric liver. Integration site analysis across all treated animals showed no dominant clonal outgrowth, a key safety signal.

This study adds important depth to the case for liver-directed lentiviral approaches in pediatric inborn errors of metabolism. Unlike AAV-based strategies, which risk dilution as a child's liver grows, lentiviral vectors integrate stably into the genome and are passed to daughter cells, making them theoretically better suited for early-life intervention. The triple validation across metabolomics, lipidomics, and proteomics is unusually comprehensive for a single preclinical study, suggesting broad systemic correction rather than superficial biomarker improvement. However, mouse models of MMA have historically not translated perfectly to human disease severity, and the absence of dominant clonal expansion — while reassuring — requires long-term monitoring in eventual human trials. This work is incremental in concept but technically sophisticated in execution, likely to underpin an IND filing within the next several years.